AHA warns cardiovascular-kidney-metabolic syndrome affects most U.S. adults

The American Heart Association and American College of Cardiology issued the first-ever clinical practice guideline for cardiovascular-kidney-metabolic syndrome on June 9, 2026, giving doctors a staging system for a disorder that ties together the heart, kidneys and the body’s energy systems. The guideline is meant to move care beyond the old habit of treating obesity, diabetes, kidney disease and cardiovascular disease as separate problems.

The association defines CKM health as the interconnected functioning of those systems. When one or more of them do not work well, CKM syndrome can develop. In the AHA’s framing, it is a systemic disorder built on metabolic risk factors, chronic kidney disease and the cardiovascular system, with multi-organ dysfunction and a high rate of adverse cardiovascular outcomes.

That naming shift matters because CKM syndrome is often hidden in plain sight. The AHA’s 2023 advisory said 1 in 3 U.S. adults had three or more risk factors contributing to cardiovascular disease, metabolic disorders or kidney disease. A 2025 AHA survey found about 9 in 10 U.S. adults had not heard of CKM syndrome, even though most wanted to learn more about it.

The new guideline tries to make the condition easier to recognize in clinics. It introduces clinical staging to assess kidney, metabolic and heart function, and it lays out screening as well as prevention and treatment strategies. That could push more clinicians to look for overlap earlier, instead of waiting until damage appears in one organ system and only later connecting it to the others.

The AHA has also said CKM syndrome disproportionately affects disenfranchised populations and highlights the role of social determinants of health. That makes the condition more than a medical relabeling: the people most exposed to chronic stress, limited access to care and other structural barriers are also the ones most likely to be missed when each specialty treats a different piece of the same problem.

Insurance coverage and treatment decisions can follow that kind of reclassification. A stage-based diagnosis may help justify earlier testing, coordinated referrals and newer therapies that are often harder to obtain when risk is split among separate labels. The association’s 2023 guidance also called for both 10-year and 30-year cardiovascular risk estimates, underscoring its push to measure long-term danger across heart, kidney and metabolic disease rather than through a single snapshot.